BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Gefitinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Gefitinib\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07829926-1961@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Gefitinib: Phase 2 readout est. (NCT07829926)
DESCRIPTION:Gefitinib\, phase 2.\nStudy: Lenvatinib Plus Tislelizumab With 
 or Without Gefitinib for Advanced Liver Cancer\nEstimated primary completi
 on: November 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ge
 fitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07829926
URL:https://assetmemo.bio/drug/gefitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03333343-1961@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270712
DTEND;VALUE=DATE:20270713
SUMMARY:Gefitinib: Phase 1 readout est. (NCT03333343)
DESCRIPTION:Gefitinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Study
  of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSC
 LC\nEstimated primary completion: 12 July 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/gefitinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT03333343
URL:https://assetmemo.bio/drug/gefitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03040973-1961@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Gefitinib: Phase 2 readout est. (NCT03040973)
DESCRIPTION:Gefitinib\, phase 2.\nStudy: Study to Allow Patients Previously
  Participating in a Novartis Sponsored Trial to Continue Receiving Capmati
 nib Treatment as Single Agent or in Combination With Other Treatments or t
 he Combination Treatment Alone\nEstimated primary completion: 30 July 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/gefitinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT03040973
URL:https://assetmemo.bio/drug/gefitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07477457-1961@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Gefitinib: Phase 2 readout est. (NCT07477457)
DESCRIPTION:Gefitinib\, phase 2.\nStudy: A Study of Gefitinib\, Trametinib\
 , Disulfiram\, and Sunitinib in Addition to Standard Chemotherapy in Peopl
 e With Osteosarcoma\nEstimated primary completion: March 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/gefitinib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07477457
URL:https://assetmemo.bio/drug/gefitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07458919-1961@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20301030
DTEND;VALUE=DATE:20301031
SUMMARY:Gefitinib: Phase 1 readout est. (NCT07458919)
DESCRIPTION:Gefitinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Thera
 py for Advanced NSCLC With EGFR 19delins Mutation\nEstimated primary compl
 etion: 30 October 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/gefitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07458919
URL:https://assetmemo.bio/drug/gefitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
